[{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Blackstone Life Sciences","amount2":0.75,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.75,"dosageForm":"Intramuscular Injection","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blackstone Life Sciences","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.39000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Dexamethasone","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blackstone Life Sciences","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Nadofaragene Firadenovec","moa":"IFNA2","graph1":"Oncology","graph2":"Phase IV","graph3":"Blackstone Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Blackstone Life Sciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Blackstone Life Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Oral Suspension","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Blackstone Life Sciences","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.34000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Fursultiamine","moa":"Hepcidin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Blackstone Life Sciences","amount2":2.2999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":2.2999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Bardoxolone Methyl","moa":"Peroxisome proliferator-activated receptor gamma | Keap1\/Nrf2 | Inhibitor of nuclear factor kappa B kinase beta subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Blackstone Life Sciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Blackstone Life Sciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Blackstone Life Sciences","amount2":2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":2,"dosageForm":"Subcutaneous Injection","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Praxis Precision Medicines","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Blackstone Life Sciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Autolus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blackstone Life Sciences","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Undisclosed","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Uniquity Bio","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Solrikitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blackstone Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Uniquity Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Solrikitug","moa":"CRLF2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blackstone Life Sciences","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by Blackstone Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : MK-8226 (solrikitug), is a highly potent anti-TSLP monoclonal antibody, which is being evaluated in early-stage clinical trial for the treatment of chronic obstructive pulmonary disease and asthma.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 15, 2024

                          Lead Product(s) : Solrikitug

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Recipient : Uniquity Bio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The financing aims to fund the clinical development of MK-8226 (solrikitug), which is being evaluated in the early-stage clinical trial for chronic obstructive pulmonary disease and asthma.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          May 15, 2024

                          Lead Product(s) : Solrikitug

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Recipient : Uniquity Bio

                          Deal Size : $300.0 million

                          Deal Type : Financing

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Proceeds will fund Moderna's influenza program, including mRNA-1010, a quadrivalent flu vaccine encoding hemagglutinin (HA) glycoproteins for four strains, administered intramuscularly.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 27, 2024

                          Lead Product(s) : Seasonal Influenza Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Moderna Therapeutics

                          Deal Size : $750.0 million

                          Deal Type : Financing

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The financing will be used for the continued pipeline advancement and further development of its cell-free protein synthesis and site-specific conjugation technologies, including VAX-24, a Phase 3 ready, 24-valent next-generation pneumococcal conjugate v...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : $140.0 million

                          June 26, 2023

                          Lead Product(s) : 24-Valent Pneumococcal Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Sutro Biopharma

                          Deal Size : $390.0 million

                          Deal Type : Collaboration

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The proceeds will be used to fund the ongoing operations of the company, including Galafold (migalastat), a small molecule and the first and only oral therapy for adults with Fabry disease and an amenable GLA variant.

                          Product Name : Galafold

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 10, 2023

                          Lead Product(s) : Migalastat

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : Amicus Therapeutics

                          Deal Size : $30.0 million

                          Deal Type : Financing

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The strategic financing will support the acceleration of PTC’s robust and diversified pipeline having lead asset Translarna (ataluren), business development opportunities and general corporate purposes.

                          Product Name : Translarna

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 27, 2022

                          Lead Product(s) : Ataluren

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : PTC Therapeutics

                          Deal Size : $50.0 million

                          Deal Type : Collaboration

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The restructured agreement allows for a return on capital already invested by Blackstone, and also provides Blackstone with option to make a passive financial investment in nadofaragene firadonavec (rAd-IFN/Syn3) upon achievement of a specified regulator...

                          Product Name : Adstiladrin

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 17, 2022

                          Lead Product(s) : Nadofaragene Firadenovec

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Ferring Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : For the Sarclisa® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company to advance the development of a subcutaneous delivery for Sarclisa® with the goal of offering a unique patient-centric treatment e...

                          Product Name : Sarclisa

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 15, 2022

                          Lead Product(s) : Isatuximab,Dexamethasone,Pomalidomide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Sanofi

                          Deal Size : $330.0 million

                          Deal Type : Collaboration

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Obecabtagene Autoleucel (Obe-cel) is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies used in adult ALL and B-NHL.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 11, 2021

                          Lead Product(s) : Obecabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Autolus Therapeutics

                          Deal Size : $250.0 million

                          Deal Type : Acquisition

                          blank

                          10

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Funding will support Medtronic's Diabetes R&D, including a series of near-term programs such as the MiniMed™ 780G insulin pump system, its Personalized Closed Loop (PCL) system, extended wear infusion set, and Zeus and Synergy sensors.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          December 06, 2020

                          Lead Product(s) : Insulin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Recipient : Medtronic Plc

                          Deal Size : $337.0 million

                          Deal Type : Funding

                          blank